Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/20.500.12008/43111
Cómo citar
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Sicco, Estefanía | - |
dc.contributor.author | Cerecetto, Hugo | - |
dc.contributor.author | Calzada, Victoria | - |
dc.contributor.author | Moreno, María | - |
dc.date.accessioned | 2024-03-14T17:06:08Z | - |
dc.date.available | 2024-03-14T17:06:08Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Sicco, E, Cerecetto, H, Calzada, V [y otros autores]. "Targeted-lymphoma drug delivery system based on the Sgc8-c aptamer". Cancers. [en línea] 2023, 15(3): 922. 13 h. DOI: 10.3390/cancers15030922. | es |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.12008/43111 | - |
dc.description.abstract | Aptamers are emerging as a promising new class of functional nucleic acids because they can specifically bind to any target with high affinity and be easily modified chemically with different pharmacophoric subunits for therapy. The truncated aptamer, Sgc8-c, binds to tyrosine-protein kinaselike 7 receptor, a promising cancer therapeutic target, allowing the recognition of haemato-oncological malignancies, among others. We have previously developed aptamer-drug conjugates by chemical synthesis, hybridizing Sgc8-c and dasatinib, a drug proposed for lymphoma chemotherapy. One of the best-characterised Sgc8-c-dasatinib hybrids, namely Sgc8-c-carb-da, was capable of releasing dasatinib at an endosomal-pH. Herein, we probed the therapeutic potential of this aptamer-drug conjugate. Sgc8-c-carb-da specifically inhibited murine A20 B lymphocyte growth and produced cell death, mainly by late apoptosis and necrosis. In addition, Sgc8-c-carb-da generated an arrest in cell proliferation, with a cell cycle arrest in the Sub-G1-peak. The mitochondrial potential was altered accordingly to these pathways. Moreover, using an in vitro cell-targeting assay that mimics in vivo conditions, we showed that Sgc8-c-carb-da displayed higher (2.5-fold) cytotoxic effects than dasatinib. These findings provide proof-of-concept of the therapeutic value of Sgc8-c-carb-da for lymphoma, creating new opportunities for the chemical synthesis of targeted biotherapeutics. | es |
dc.description.sponsorship | ANII: POS_NAC_2017_1_140364 | es |
dc.format.extent | 13 h. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | en | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Cancers, 2023, 15(3): 922. | es |
dc.rights | Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014) | es |
dc.subject | Lymphoma | es |
dc.subject | Aptamer | es |
dc.subject | Drug delivery | es |
dc.subject | Aptamer-drug conjugates | es |
dc.subject | Biotherapeutics | es |
dc.subject | PTK7 | es |
dc.title | Targeted-lymphoma drug delivery system based on the Sgc8-c aptamer | es |
dc.type | Artículo | es |
dc.contributor.filiacion | Sicco Estefanía, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares. | - |
dc.contributor.filiacion | Cerecetto Hugo, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares. | - |
dc.contributor.filiacion | Calzada Victoria, Universidad de la República (Uruguay). Facultad de Ciencias. Centro de Investigaciones Nucleares. | - |
dc.contributor.filiacion | Moreno María, Universidad de la República (Uruguay). Facultad de Medicina. | - |
dc.rights.licence | Licencia Creative Commons Atribución (CC - By 4.0) | es |
dc.identifier.doi | 10.3390/cancers15030922 | - |
Aparece en las colecciones: | Publicaciones académicas y científicas - Facultad de Ciencias |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | ||
---|---|---|---|---|---|
10.3390.cancers15030922.pdf | 2,24 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons